Literature DB >> 32045384

Mesenchymal stromal cells shape the MDS microenvironment by inducing suppressive monocytes that dampen NK cell function.

Dhifaf Sarhan1,2, Jinhua Wang3,4, Upasana Sunil Arvindam3, Caroline Hallstrom3, Michael R Verneris5, Bartosz Grzywacz6, Erica Warlick1, Bruce R Blazar7, Jeffrey S Miller1,3.   

Abstract

Altered BM hematopoiesis and immune suppression are hallmarks of myelodysplastic syndrome (MDS). While the BM microenvironment influences malignant hematopoiesis, the mechanism leading to MDS-associated immune suppression is unknown. We tested whether mesenchymal stromal cells (MSCs) contribute to this process. Here, we developed a model to study cultured MSCs from patients with MDS (MDS-MSCs) compared with those from aged-matched normal controls for regulation of immune function. MDS-MSCs and healthy donor MSCs (HD-MSCs) exhibited a similar in vitro phenotype, and neither had a direct effect on NK cell function. However, when MDS- and HD-MSCs were cultured with monocytes, only the MDS-MSCs acquired phenotypic and metabolic properties of myeloid-derived suppressor cells (MDSCs), with resulting suppression of NK cell function, along with T cell proliferation. A MSC transcriptome was observed in MDS-MSCs compared with HD-MSCs, including increased expression of the ROS regulator, ENC1. High ENC1 expression in MDS-MSCs induced suppressive monocytes with increased INHBA, a gene that encodes for a member of the TGF-β superfamily of proteins. These monocytes also had reduced expression of the TGF-β transcriptional repressor MAB21L2, further adding to their immune-suppressive function. Silencing ENC1 or inhibiting ROS production in MDS-MSCs abrogated the suppressive function of MDS-MSC-conditioned monocytes. In addition, silencing MAB21L2 in healthy MSC-conditioned monocytes mimicked the MDS-MSC-suppressive transformation of monocytes. Our data demonstrate that MDS-MSCs are responsible for inducing an immune-suppressive microenvironment in MDS through an indirect mechanism involving monocytes.

Entities:  

Keywords:  Adaptive immunity; Bone marrow; Cancer immunotherapy; Immunology

Mesh:

Substances:

Year:  2020        PMID: 32045384      PMCID: PMC7141401          DOI: 10.1172/jci.insight.130155

Source DB:  PubMed          Journal:  JCI Insight        ISSN: 2379-3708


  48 in total

Review 1.  Cellular and molecular interactions of mesenchymal stem cells in innate immunity.

Authors:  Grazia Maria Spaggiari; Lorenzo Moretta
Journal:  Immunol Cell Biol       Date:  2012-11-13       Impact factor: 5.126

2.  Low expression of ENC1 predicts a favorable prognosis in patients with ovarian cancer.

Authors:  Shaohua Fan; Yanyan Wang; Ning Sheng; Ying Xie; Jun Lu; Zifeng Zhang; Qun Shan; Dongmei Wu; Chunhui Sun; Mengqiu Li; Bin Hu; Yuanlin Zheng
Journal:  J Cell Biochem       Date:  2018-08-20       Impact factor: 4.429

3.  CD16xCD33 bispecific killer cell engager (BiKE) activates NK cells against primary MDS and MDSC CD33+ targets.

Authors:  Michelle K Gleason; Julie A Ross; Erica D Warlick; Troy C Lund; Michael R Verneris; Andres Wiernik; Stephen Spellman; Michael D Haagenson; Alexander J Lenvik; Mark R Litzow; Pearlie K Epling-Burnette; Bruce R Blazar; Louis M Weiner; Daniel J Weisdorf; Daniel A Vallera; Jeffrey S Miller
Journal:  Blood       Date:  2014-03-20       Impact factor: 22.113

4.  Mesenchymal stem cells inhibit natural killer-cell proliferation, cytotoxicity, and cytokine production: role of indoleamine 2,3-dioxygenase and prostaglandin E2.

Authors:  Grazia Maria Spaggiari; Andrea Capobianco; Heba Abdelrazik; Flavio Becchetti; Maria Cristina Mingari; Lorenzo Moretta
Journal:  Blood       Date:  2007-10-19       Impact factor: 22.113

5.  Mesenchymal stem cells can be differentiated into endothelial cells in vitro.

Authors:  Joachim Oswald; Sabine Boxberger; Birgitte Jørgensen; Silvia Feldmann; Gerhard Ehninger; Martin Bornhäuser; Carsten Werner
Journal:  Stem Cells       Date:  2004       Impact factor: 6.277

6.  Mesenchymal stromal cells derived from acute myeloid leukemia bone marrow exhibit aberrant cytogenetics and cytokine elaboration.

Authors:  J C Huang; S K Basu; X Zhao; S Chien; M Fang; V G Oehler; F R Appelbaum; P S Becker
Journal:  Blood Cancer J       Date:  2015-04-10       Impact factor: 11.037

7.  Correction: Bone marrow MSCs in MDS: contribution towards dysfunctional hematopoiesis and potential targets for disease response to hypomethylating therapy.

Authors:  Zhiyong Poon; Niraja Dighe; Subhashree S Venkatesan; Alice M S Cheung; Xiubo Fan; Sudipto Bari; Monalisa Hota; Sujoy Ghosh; William Y K Hwang
Journal:  Leukemia       Date:  2019-06       Impact factor: 11.528

Review 8.  In vitro differentiation of embryonic and adult stem cells into hepatocytes: state of the art.

Authors:  Sarah Snykers; Joery De Kock; Vera Rogiers; Tamara Vanhaecke
Journal:  Stem Cells       Date:  2009-03       Impact factor: 6.277

Review 9.  Mesenchymal stem cells and immunomodulation: current status and future prospects.

Authors:  F Gao; S M Chiu; D A L Motan; Z Zhang; L Chen; H-L Ji; H-F Tse; Q-L Fu; Q Lian
Journal:  Cell Death Dis       Date:  2016-01-21       Impact factor: 8.469

10.  Myeloid-derived suppressor cells inhibit T cell proliferation in human extranodal NK/T cell lymphoma: a novel prognostic indicator.

Authors:  Han Zhang; Ze-Lei Li; Shu-Biao Ye; Li-Ying Ouyang; Yu-Shan Chen; Jia He; Hui-Qiang Huang; Yi-Xin Zeng; Xiao-Shi Zhang; Jiang Li
Journal:  Cancer Immunol Immunother       Date:  2015-10-23       Impact factor: 6.968

View more
  16 in total

Review 1.  Myelodysplastic syndrome and immunotherapy novel to next in-line treatments.

Authors:  Katherine Linder; Premal Lulla
Journal:  Hum Vaccin Immunother       Date:  2021-05-03       Impact factor: 3.452

Review 2.  Myeloid-Derived Suppressor Cells in the Context of Allogeneic Hematopoietic Stem Cell Transplantation.

Authors:  Maud D'Aveni; Anne B Notarantonio; Allan Bertrand; Laura Boulangé; Cécile Pochon; Marie T Rubio
Journal:  Front Immunol       Date:  2020-05-22       Impact factor: 7.561

Review 3.  Tumor Microenvironment Uses a Reversible Reprogramming of Mesenchymal Stromal Cells to Mediate Pro-tumorigenic Effects.

Authors:  Armel H Nwabo Kamdje; Paul F Seke Etet; Richard Simo Tagne; Lorella Vecchio; Kiven Erique Lukong; Mauro Krampera
Journal:  Front Cell Dev Biol       Date:  2020-11-19

Review 4.  Emerging data supporting stromal cell therapeutic potential in cancer: reprogramming stromal cells of the tumor microenvironment for anti-cancer effects.

Authors:  Armel H Nwabo Kamdje; Paul F Seke Etet; Richard Tagne Simo; Lorella Vecchio; Kiven Erique Lukong; Mauro Krampera
Journal:  Cancer Biol Med       Date:  2020-12-15       Impact factor: 4.248

Review 5.  Cytokines Orchestrating the Natural Killer-Myeloid Cell Crosstalk in the Tumor Microenvironment: Implications for Natural Killer Cell-Based Cancer Immunotherapy.

Authors:  Silvia Gaggero; Kristina Witt; Mattias Carlsten; Suman Mitra
Journal:  Front Immunol       Date:  2021-01-29       Impact factor: 7.561

Review 6.  Mesenchymal Stem Cell: A Friend or Foe in Anti-Tumor Immunity.

Authors:  Carl Randall Harrell; Ana Volarevic; Valentin G Djonov; Nemanja Jovicic; Vladislav Volarevic
Journal:  Int J Mol Sci       Date:  2021-11-18       Impact factor: 5.923

Review 7.  Immune Dysfunction, Cytokine Disruption, and Stromal Changes in Myelodysplastic Syndrome: A Review.

Authors:  Olivia F Lynch; Laura M Calvi
Journal:  Cells       Date:  2022-02-08       Impact factor: 6.600

Review 8.  Characteristics and regulation of mesenchymal stem cell plasticity by the microenvironment - specific factors involved in the regulation of MSC plasticity.

Authors:  Liping Tan; Xuan Liu; Huan Dou; Yayi Hou
Journal:  Genes Dis       Date:  2020-10-27

Review 9.  Mesenchymal Stem Cells in Aplastic Anemia and Myelodysplastic Syndromes: The "Seed and Soil" Crosstalk.

Authors:  Bruno Fattizzo; Juri A Giannotta; Wilma Barcellini
Journal:  Int J Mol Sci       Date:  2020-07-30       Impact factor: 5.923

10.  Bone marrow derived stromal cells from myelodysplastic syndromes are altered but not clonally mutated in vivo.

Authors:  Johann-Christoph Jann; Maximilian Mossner; Vladimir Riabov; Eva Altrock; Nanni Schmitt; Johanna Flach; Qingyu Xu; Verena Nowak; Julia Obländer; Iris Palme; Nadine Weimer; Alexander Streuer; Ahmed Jawhar; Ali Darwich; Mohammad Jawhar; Georgia Metzgeroth; Florian Nolte; Wolf-Karsten Hofmann; Daniel Nowak
Journal:  Nat Commun       Date:  2021-10-25       Impact factor: 14.919

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.